Julian Upton

Biopharma experts at the forefront of applying real-world data and real-world evidence across the product life cycle converge to discuss the lingering challenges in fully realizing the vast potential of these insights to transform the value equation.

With more promising products emerging, investment risks remain.

After helping lead Novo Nordisk on a transformational journey from a troubled 2016 to double-digit growth in 2021, Doug Langa, Executive Vice President, Head of North America Operations and President of Novo Nordisk, Inc., is calling on his experience of taking the less conventional and sometimes unexpected routes to success to lead Novo Nordisk into new territory.

A new report examining pharma sector exposure makes for sobering reading, especially in US.

Illinois BIO‘s (iBIO) new chairperson, Horizon Therapeutic‘s Marilyn Vetter, outlines the work she plans to do to expand the state’s existing life sciences ecosystem.

Spurred on by COVID-19 and companies’ evolving digital maturity, AI looks set to gain a real foothold in pharma’s promotional activities.

Government-led programs aim to attract scientists and offer resources to growing industry.

As borders shut down during the pandemic, pharma learned some lessons about sourcing.

Myrtle Potter is no stranger to overcoming adversity. As CEO of Sumitovant Biopharma, she has used her entrepreneurship, determination, and inclusive attitude to help her persevere and achieve her highest goals while overseeing five companies—Myovant, Urovant, Enzyvant, Altavant, and Spirovant.

The constantly evolving world of data is forcing pharma companies to implement new strategies for improved structure.

Ahead of the release of EY’s annual M&A Firepower report this week, Pharm Exec talks to EY’s Arda Ural to review biopharma M&A activity in 2021 and to discuss the likely deal drivers of 2022.

As the pressure on teams reviewing promotional content has increases, both in terms of volumes of content and complexity, Sameer Lal discusses the need for a near-term strategies using artificial intelligence (AI) and machine learning (ML) to decongest bottlenecks of the manual review process.

After two decades at the forefront of hematology and oncology drug development, AbbVie’s vice president and global head of oncology clinical development, Mohamed Zaki, MD, PhD, is more hopeful than ever about recent advances in the space.

Critics proclaim that recent RWD guidance issued by FDA still has a good number of gaps to fill and may take some time to accomplish.

Cyclacel CEO Spiro Rombotis talks about the changes he has seen during his 36-year experience in pharma and biotech and how he continues to be motivated by Cyclacel’s work on solid tumors and lymphomas.

Pharma organizations have long been vigilant in protecting their intellectual property and financial information, but the disruption of COVID-19 has seen an expansion of the ‘cyberattack surface.’

Traditionally difficult in pharma, data science recruitment witnessed a sharp drop-off at the beginning of the pandemic, but interest has since bounced back to unexpected levels.

Looking back at 2015–2018.

Mark Materacky talks about Novo Nordisk and Queen Latifah’s “It's Bigger Than Me” campaign to change the way the world looks at and discusses obesity.

While there is broad agreement that the Chief Data Officer plays a critical part in pharma, a definitive description of the role is still evolving.

How the sharing of scientific content with HCPs is shifting in an era of accelerated digitalization.

Lorna Meldrum, Vice President, Commercial Operations, International Markets & Pandemic at Seqirus, talks about the challenges of the influenza vaccine market and how COVID-19 has highlighted that preventing ’flu is crucial for public health.

New drug aims to turn obesity into treatable chronic condition.

Teva CEO Kåre Schultz talks about his long industry experience tackling major strategic and operational challenges, and how he is progressing on his current mission to turn around Teva’s fortunes.

Digital transformation in medical affairs made a sluggish start, but there is plenty to be optimistic about.

AstraZeneca’s Mina Makar and Amgen’s Kave Niksefat talk about how the two companies worked together to develop the new asthma treatment, tezepelumab.

Accelerated implementation of AI platforms among pharma sales teams has highlighted the importance of the human factor.

GSK‘s President of US Pharmaceuticals, Maya Martinez-Davis, outlines her organization’s evolving diversity and inclusion commitments.

Along with the industry’s massive effort to tackle the health and social problems exposed by COVID, pharma companies have spent the last year addressing the internal impact of racial inequalities following the murder of George Floyd.

Alnylam's new Chief Commercial Officer, Tolga Tanguler, talks about his new role and what he envisions for the company in the next five years.